Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
Gross Profit
Innovent Biologics Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Innovent Biologics Inc
HKEX:1801
|
Gross Profit
¥5.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Gross Profit
¥14.7B
|
CAGR 3-Years
108%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Gross Profit
¥4.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
S
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Gross Profit
¥3.1B
|
CAGR 3-Years
22%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Gross Profit
¥13.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Gross Profit
¥1.8B
|
CAGR 3-Years
53%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
See Also
What is Innovent Biologics Inc's Gross Profit?
Gross Profit
5.1B
CNY
Based on the financial report for Dec 31, 2023, Innovent Biologics Inc's Gross Profit amounts to 5.1B CNY.
What is Innovent Biologics Inc's Gross Profit growth rate?
Gross Profit CAGR 3Y
14%
Over the last year, the Gross Profit growth was 40%. The average annual Gross Profit growth rates for Innovent Biologics Inc have been 14% over the past three years .